Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 8:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–22 of 22 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company Clear all
Recruiting Phase 4 Interventional Accepts healthy volunteers

Study to Assess Safety and Tolerability of KarXT With Administration of Antiemetics in Healthy Volunteers

NCT07681076
View directory record Official record
Conditions
Healthy Volunteers
Interventions
KarXT, Trimethobenzamide, Ondansetron, Meclizine
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
18 Years to 65 Years
Enrollment
225 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
4
States / cities
Los Alamitos, California • Hollywood, Florida • Atlanta, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 9, 2026, 8:08 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

KarXT Concentrations in the Breast Milk and Plasma of Lactating Females

NCT07257120
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Xanomeline/trospium chloride
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 9, 2026, 8:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effects of KarXT on the Drug Levels of Midazolam, Fexofenadine, and Digoxin

NCT07118215
View directory record Official record
Conditions
Healthy Volunteers
Interventions
KarXT, Midazolam, Fexofenadine, Digoxin
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
18 Years to 50 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 9, 2026, 8:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium

NCT02831231
View directory record Official record
Conditions
Schizophrenia
Interventions
xanomeline tartrate, Trospium chloride
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
18 Years to 60 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Oct 9, 2026, 8:08 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy Adult Participants

NCT07204418
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Xanomeline/ Trospium Chloride
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Anaheim, California • Lenexa, Kansas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 9, 2026, 8:08 PM EDT
Terminated Phase 3 Interventional Results available

An Open-label Study to Assess the Long-term Safety, Tolerability, Effectiveness, and Durability of Effect of KarXT in Patients With DSM-5 Diagnosis of Schizophrenia

NCT05643170
View directory record Official record
Conditions
Schizophrenia
Interventions
Xanomeline and Trospium Chloride Capsules
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
Atlanta, Georgia • Louisville, Kentucky • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2024 · Synced Oct 9, 2026, 8:08 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess Safety and Efficacy of KarXT in Adult Patients With Schizophrenia

NCT03697252
View directory record Official record
Conditions
Schizophrenia
Interventions
Xanomeline and Trospium Chloride Capsules, Placebo Capsules
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
18 Years to 60 Years
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
12
States / cities
Little Rock, Arkansas • Lemon Grove, California • Long Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2020 · Synced Oct 9, 2026, 8:08 PM EDT
Recruiting Phase 3 Interventional

Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

NCT05980949
View directory record Official record
Conditions
Psychosis Associated With Alzheimer's Disease
Interventions
KarXT
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
55 Years to 90 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
147
States / cities
Homewood, Alabama • Chandler, Arizona • Gilbert, Arizona + 92 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 9, 2026, 8:08 PM EDT
Completed Phase 3 Interventional

An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

NCT05304767
View directory record Official record
Conditions
Schizophrenia
Interventions
Xanomeline and Trospium Chloride Capsules
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
18 Years to 65 Years
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
56
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 9, 2026, 8:08 PM EDT
Recruiting Phase 3 Interventional

Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia

NCT07686263
View directory record Official record
Conditions
Schizophrenia
Interventions
Xanomeline/Trospium Chloride, Placebo
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
18 Years to 65 Years
Enrollment
472 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
34
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Rogers, Arkansas + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 9, 2026, 8:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of Xanomeline With Trospium Chloride Versus KarXT in Healthy Adult and Elderly Participants of Japanese Ethnicity and to Assess the Effect of Omeprazole on the PK of Xanomeline With Trospium Chloride in Healthy Adult Participants

NCT06605950
View directory record Official record
Conditions
Healthy Volunteers
Interventions
KarXT, KarX-EC, Placebo, Omeprazole
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
19 Years to 90 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Jul 4, 2025 · Synced Oct 9, 2026, 8:08 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

NCT06585787
View directory record Official record
Conditions
Alzheimer Disease
Interventions
KarXT, Placebo
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
55 Years to 90 Years
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
102
States / cities
Chandler, Arizona • Gilbert, Arizona • Phoenix, Arizona + 71 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 9, 2026, 8:08 PM EDT
Recruiting Phase 3 Interventional

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)

NCT05511363
View directory record Official record
Conditions
Psychosis Associated With Alzheimer's Disease
Interventions
KarXT, Placebo
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
55 Years to 90 Years
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
59
States / cities
Homewood, Alabama • Phoenix, Arizona • Encino, California + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 9, 2026, 8:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effects of Lithium, Valproic Acid, and Lamotrigine on the Pharmacokinetics of KarXT and Effects of KarXT on the Pharmacokinetics of Lithium, Valproic Acid, and Lamotrigine in Healthy Participants

NCT06729970
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Xanomeline/Trospium Chloride, Lithium, Valproic Acid, Lamotrigine
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
18 Years to 65 Years
Enrollment
133 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Los Alamitos, California
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 9, 2026, 8:08 PM EDT
Recruiting Phase 3 Interventional

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)

NCT06126224
View directory record Official record
Conditions
Psychosis Associated With Alzheimer's Disease
Interventions
KarXT, Placebo
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
55 Years to 90 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
70
States / cities
Chandler, Arizona • Phoenix, Arizona • Anaheim, California + 43 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 9, 2026, 8:08 PM EDT
Completed Phase 3 Interventional Results available

An Extension Study to Assess Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-4)

NCT04659174
View directory record Official record
Conditions
Schizophrenia
Interventions
Xanomeline and Trospium Chloride Capsules
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
18 Years to 65 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
34
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Anaheim, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2024 · Synced Oct 9, 2026, 8:08 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-3)

NCT04738123
View directory record Official record
Conditions
Schizophrenia, Schizophrenia; Psychosis
Interventions
Xanomeline and Trospium Chloride Capsules, Placebo
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
18 Years to 65 Years
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
20
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Anaheim, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Oct 9, 2026, 8:08 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-2)

NCT04659161
View directory record Official record
Conditions
Schizophrenia, Schizophrenia; Psychosis
Interventions
Xanomeline and Trospium Chloride Capsules, Placebo
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
18 Years to 65 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
22
States / cities
Little Rock, Arkansas • Bellflower, California • Culver City, California + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Oct 9, 2026, 8:08 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

NCT05145413
View directory record Official record
Conditions
Schizophrenia
Interventions
Xanomeline and Trospium Chloride Capsules, Placebo
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
18 Years to 65 Years
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
79
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 61 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 9, 2026, 8:08 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess Safety and Effectiveness of Slowly Increasing Dose and Food Effect of KarXT in Participants With Schizophrenia

NCT06572449
View directory record Official record
Conditions
Schizophrenia
Interventions
KarXT
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
18 Years to 65 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
6
States / cities
Los Alamitos, California • Riverside, California • Hollywood, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 9, 2026, 8:08 PM EDT
Completed Phase 3 Interventional Results available

An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)

NCT04820309
View directory record Official record
Conditions
Schizophrenia
Interventions
Xanomeline and Trospium Chloride Capsules
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
18 Years to 65 Years
Enrollment
566 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
116
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Anaheim, California + 56 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 9, 2026, 8:08 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents

NCT07424404
View directory record Official record
Conditions
Schizophrenia, Autism-Related Irritability
Interventions
KarXT, KarX-EC
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
5 Years to 17 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
51
States / cities
Dothan, Alabama • Phoenix, Arizona • Anaheim, California + 43 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 9, 2026, 8:08 PM EDT